On Wednesday, the shares of Mumbai-based drug maker Lupin declined after the company revealed that billionaire Investor Rakesh Jhunjhunwala has sold his shares in the company worth more than Rs 300 crore in the first quarter.

The stock of lupin was traded at Rs 461.20 in the intra-day on the BSE, which was 3.7% less than its previous close.

INVESTMENT THESIS - Lupin is among the best players in the generic space given its strong execution capabilities and diversifying business model. To overcome volatilities in price erosion in the pure Vanilla Generic Segment, it has also built a formidable presence in the Branded Generic Segment.

• It has stellar supply-chain execution as it has garnered strong market share gains in the US in most major products, sometimes even from industry leaders like Teva and Sandoz. It is now the sixth-largest pharmaceutical company in the US by volume, indicating the trust it enjoys of major pharmacies and distributors.

Technical analyst Ashish Maheshwari of Global Capital Market is bullish on Lupin Limited and has maintained 'hold' rating on the stock.

According to the analyst, the interested investors can add more on dips of 5-7% from current levels.

Today, the stock of the company opened at Rs 389 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 519.80 and a low of Rs 317 on BSE.

Current EPS & P/E ratio stood at 19.19 and 20.06 respectively.

Lupin is one of the best plays in the pharma space, given its strong execution capabilities, improving financial performance and diversifying business model. The high-margin branded generic business has been the key differentiator. Strong growth on the US front (both branded generic and generic segments) and improvement in operating margins would maintain the growth momentum.

1) Strong traction in the high-margin Suprax product (chewable tablets approved; double strength tablets now enjoy more than 50% of total Suprax prescription share) and gradual pick up in Antara prescription.

Lupin Q3FY2011 results were in-line with estimates but single digit growth on US segment front was the disappointment. The management attributed this to inventory rationalisation in channels and change in accounting policy for rebates. Going ahead the company expects inventory in channels to pick-up to normal level. We recommend BUY on the stock with a target price of Rs537 valuing the stock at 22x FY2012E earnings. We believe the recent weakness in stock is a good entry point as long term drivers (OC launches in US, improvement of margins in Japan business, strong growth in India and other markets) are intact.

Indian groups appears to be under pressure to match steps with their Chinese competitors, divulges Boston Consultancy Group (BCG) review that picks out groups with ability to locate a position in the Fortune Global 500 association in the upcoming five years.

Just two Indian groups discovered a position in BCG's fourth version of the annual report on year's 100 "growing stars" of business through rising nations, as against 10 from China.

Technical analyst PK Agarwal of Purpleline Investment has maintained 'hold' rating on Lupin Limited stock with medium-to-long term view.

According to analyst, the investors can buy the stock with a stop loss of Rs 425.

Today, the stock of the company opened at Rs 468 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 519.80 and a low of Rs 277 on BSE.

Current EPS & P/E ratio stood at 17.78 and 25.48 respectively.

Stock market analyst MB Singh has maintained 'buy' rating on Lupin Ltd stock with a target of Rs 520.

According to analyst, the interested investors can buy the stock with a stop loss of Rs 482.

The stock of the company, on Nov 18, closed at Rs 492.90 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 17.78 and 27.99 respectively.

The share price has seen a 52-week high of Rs 498 and a low of Rs 267 on BSE.

Stock market analyst Varun Daga has maintained 'buy' rating on Lupin Ltd stock to achieve a long term target of Rs 2010.

According to analyst, the interested investors can purchase the stock with stop loss of Rs 1785.

Today, the stock of the company opened at Rs 1881.25 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 76.61 and 24.76 respectively.

The share price has seen a 52-week high of Rs 1970 and a low of Rs 780 on BSE.

Pharmaceutical major Lupin will establish a research and development (R&D) unit in Aurangabad to make generic drug products to fulfill the growing demand in Latin America, Africa and Australia.

The company will employ around 50 to 60 people for its new research and development facility, which is likely to be completed by the next in three months.

Mr. Nilesh Gupta, group president and executive director said that the company presently has an R&D team of 700-plus scientists.

Technical Analyst Radhika Gupta of Forefront Capital Management has maintained 'buy' rating on Lupin Ltd stock.

According to analyst, the investors can buy the stock to reap good returns in the long run.

Today, the stock of the company opened at Rs 1860 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1881 and a low of Rs 754.90 on BSE.

Current EPS & P/E ratio stood 76.61 and 23.91 respectively.

India's leading Pharmaceutical Company Lupin has informed that it will launch a product in a new segment every year. The drug maker is expected to enhance its stand in the countries like US, Japan along with the Indian market.

For this it need several fresh products and for every segment as well. The coming years are expected to be prospective for the company so far as annual growth is concerned. The company has also said that it will launch an oral contraceptive product in the next fiscal year. This will be a new product from the company in that segment.

Pharmaceutical company, Lupin on Wednesday reported a 40.18 per cent increase in its net profit. As per the recently announced results, the profit of the company has become Rs. 220.62 crore for the fourth quarter of last year that ended on March 31. This rise has been calculated over the last year period.

The total income of the company also increased during the period. It increased from Rs. 1,069 crore during last year to touch Rs. 1,338.6 crore, for the Q4 period. This information was revealed in the report submitted by Lupin to the BSE.

Indian pharmaceutical company Lupin on Thursday launched its new medicine for degenerative joint disease osteoarthritis, Hyalgan. It's an injectable liquid drug to relieve a patient from pain caused from osteoarthritis, a company statement said. The drug is injected directly into the knees.

Nearly 12 per cent of the population in India is affected by osteoarthritis, which is a major health problem in the country today among the 25-30 age group. As revealed by a survey at present the market for such medicines worth nearly Rs. 150 crore, Lupin said in its statement.

Drug major Lupin announced that the US Food and Drug Administration (USFDA) has granted tentative approval to its Perindopril Erbumine tabs in the potencies of 2mg, 4mg and 8mg.

Lupin's perindopril erbumine pills generic version of Solvay Pharmaceuticals' Aceon tabs used to treat high blood pressure and management of arterial sclerosis.

In a declaration, the company said, "Commercial shipments of the product will commence soon."

Stock market analysts have maintained 'buy' rating on Lupin Ltd with an intraday target of Rs 1395.

According to them, interested traders can purchase the stock above Rs 1381 with a strict stop loss of Rs 1365.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 1405.

Shares of the company, on Thursday (Nov 27), closed at Rs 1373.65 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1365 and a low of Rs 525 on BSE.

Current EPS & P/E ratio stood at 66.64 and 20.52 respectively.

Lupin, one of the leading pharmaceutical companies in India, has posted disappointing results for the second quarter ended September 30, 2009.

The company posted a net profit of Rs 98.37 crore for the second quarter ended September 30, 2009 as against Rs 131.94 crore for the quarter ended September 30, 2008.

However, the company remained successful to register a surge in its total income, which grew from Rs 772.44 crore for the quarter ended September 30, 2008 to Rs 846.09 crore for the quarter ended September 30, 2009.

Lupin, one of the leading pharmaceutical companies in India, has finally granted Nasdaq-listed Salix Pharmaceuticals, the exclusive rights in the United States to its bioadhesive drug delivery technology for use with Rifaximin.

Lupin and Salix have entered into a deal under which both partners will collaborate in the development and commercialization of an extended release product incorporating Rifaximin and utilizing Lupin’s proprietary bioadhesive technology.

Lupin, one of the leading pharmaceutical company, has acquired the rights for Antara for $38.61 million from the US-based Oscient Pharmaceuticals.

The company stated in a communiqué that rights for the drug, along with related assets and inventories, have been acquired under the procedures of the US Bankruptcy Court.

The drug is used to treat high blood cholesterol and high triglycerides. Fenofibrate capsules had $70 million (Rs 337.5 crore) worth of sales in the US market in 2008.